Clovis Oncology (CLVS) Posts Smaller Q2 Loss, Sales Beat

Clovis Oncology (NASDAQ: CLVS) reported Q2 EPS of ($1.29), $0.84 better than the analyst estimate of ($2.13). Revenue for the quarter came in at $14.62 million versus the consensus estimate of $13.31 million.

For earnings history and earnings-related data on Clovis Oncology (CLVS) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Innovaro (INV) Misses Q2 EPS by 9c
• 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c